216 related articles for article (PubMed ID: 17244680)
1. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
2. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
4. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
5. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
6. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.
Puccetti E; Obradovic D; Beissert T; Bianchini A; Washburn B; Chiaradonna F; Boehrer S; Hoelzer D; Ottmann OG; Pelicci PG; Nervi C; Ruthardt M
Cancer Res; 2002 Dec; 62(23):7050-8. PubMed ID: 12460926
[TBL] [Abstract][Full Text] [Related]
7. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
[TBL] [Abstract][Full Text] [Related]
9. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines.
Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M
Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112
[TBL] [Abstract][Full Text] [Related]
10. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
[TBL] [Abstract][Full Text] [Related]
14. Dominant negative effects of the AML1/ETO fusion oncoprotein.
Fenske TS; Pengue G; Graubert TA
Cell Cycle; 2005 Jan; 4(1):33-6. PubMed ID: 15611635
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line.
Zhuang WY; Cen JN; Zhao Y; Chen ZX
Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.
de Guzman CG; Warren AJ; Zhang Z; Gartland L; Erickson P; Drabkin H; Hiebert SW; Klug CA
Mol Cell Biol; 2002 Aug; 22(15):5506-17. PubMed ID: 12101243
[TBL] [Abstract][Full Text] [Related]
17. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.
Peterson LF; Yan M; Zhang DE
Blood; 2007 May; 109(10):4392-8. PubMed ID: 17284535
[TBL] [Abstract][Full Text] [Related]
18. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
Müller-Tidow C; Steffen B; Cauvet T; Tickenbrock L; Ji P; Diederichs S; Sargin B; Köhler G; Stelljes M; Puccetti E; Ruthardt M; deVos S; Hiebert SW; Koeffler HP; Berdel WE; Serve H
Mol Cell Biol; 2004 Apr; 24(7):2890-904. PubMed ID: 15024077
[TBL] [Abstract][Full Text] [Related]
19. AML-1-ETO-Mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein.
Choi Y; Elagib KE; Goldfarb AN
Crit Rev Eukaryot Gene Expr; 2005; 15(3):207-16. PubMed ID: 16390317
[TBL] [Abstract][Full Text] [Related]
20. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
